La cadena de opciones muestra datos clave de las opciones de acciones de Tactile Systems Tech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Tactile Systems Tech..

Tactile Systems Tech (NASDAQ:TCMD) Bolsa, Cadena de Opciones

Tactile Systems Tech

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Technology Inc

<a href="https://www.benzinga.com/real-estate/24/12/42368125/i-wonder-how-young-people-today-survive-robert-kiyosaki-says-spending-14-on-an-egg-salad-sandwich-was-hard-to-swallow">Robert Kiyosaki</a>, the author of Rich Dad Poor Dad, has never been shy about making bold predictions. On Jan. 26, he took to X to double down on what <a href="https://www.benzinga.com/personal-finance/24/07/40041316/laugh-all-you-want-robert-kiyosaki-rich-dad-poor-dad-warns-millions-of-401-k-s-and-iras-will-be-">he's been warning about for years</a>: a massive stock market crash. This time, though, he's naming a specific date – February 2025 – as the tipping point for what he calls "the biggest stock market crash in history."
In his post, Kiyosaki referenced his 2013 book, Rich Dad's Prophecy, where he claimed this crash was inevitable. But it's not just doom and gloom from him. Kiyosaki argues that market crashes create opportunities for those prepared, saying everything from cars to houses will "go on sale." He wrote, "Good news because in a crash everything goes on sale. Cars and houses on sale now."
Don't Miss:
<ul>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Even more interestingly, he predicts that billions will leave traditional investments like stocks and bonds, flowing into assets like Bitcoin, gold and silver. He advises people to "get out of fake and into real," emphasizing that even owning a single Satoshi could be enough to secure wealth in the chaos.
But Kiyosaki isn't alone in predicting trouble.
Goldman Sachs analysts also warn of a significant market correction, estimating a potential 30% drop in 2025. Their concerns stem from high valuations and ongoing economic uncertainty. Economist Harry Dent is on a similar page, pointing to <a href="https://www.benzinga.com/personal-finance/24/11/42236424/1-in-5-dollars-the-government-expends-goes-to-repaying-investors-heres-why-this-spells-trouble-for-trump-and-doge">America's growing private debt</a> as a time bomb waiting to go off. Dent has even said the bubble could burst as early as mid-2025.
Trending: Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce">this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.</a>
Meanwhile, Jeremy Grantham, a veteran investor known for spotting financial bubbles, is predicting a "cataclysmic decline" in the stock market. He attributes this to overvaluation, demographic shifts like declining population growth, and global challenges such as climate change.
With heavyweights like Kiyosaki, Goldman Sachs, Dent and Grantham all predicting a downturn, the message is clear: prepare now. While the specifics of these warnings differ, they all share a common theme – markets are fragile, and significant challenges are ahead.
For the average investor, this means reassessing your financial strategy. Diversification becomes even more critical in uncertain times. Kiyosaki suggests moving from traditional "fake" assets like stocks and bonds into alternatives like cryptocurrency, gold and silver. While his Bitcoin predictions of "boom, boom, boom" may seem extreme, crypto has historically performed well during periods of economic uncertainty.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Experts recommend having a clear plan for market volatility. <a href="https://www.benzinga.com/personal-finance/24/08/40531988/you-dont-need-emergency-savings-says-grant-cardone-claims-that-three-months-of-savings-in-case-o">Building emergency savings</a>, paying down debt, and diversifying your investments are key steps to weather a potential storm.
No one can predict the future with absolute certainty, but financial experts' growing chorus of warnings is hard to ignore. Whether or not February 2025 brings the "biggest crash in history," it's a good time to <a href="https://www.benzinga.com/money/are-you-rich">evaluate your financial health</a> and make adjustments if needed. After all, as Kiyosaki often reminds us, in every crash lies an opportunity – if you're prepared for it.
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

News

Robert Kiyosaki, 'Rich Dad, Poor Dad,' Warns The Biggest Stock Market Crash Ever Is Coming February – 'Good News Is Everything Goes On Sale'

Outlook
The company anticipates that adjusted earnings per share for the full year 2025 will be in the range of $7.75 to $8.05, which at the mid-point represents EPS growth of 7% excluding the impact of foreign currency translation and a higher tax rate. This range is based on current global economic activity and foreign exchange rates, ongoing soft global industrial production, and mixed demand across the various regions in which we operate. The company expects that annual EPS growth will be weighted toward the second half of 2025 as global industrial demand weakened and the U.S. dollar strengthened in the second half of 2024. Additionally, we expect to realize more than $100 million in annualized share gains in our Industrial Coatings segment beginning in the second half of the year.
Additional information related to 2025 financial projections is posted within the slides and prepared commentary associated with the fourth quarter earnings documents on the Investors section of PPG.com.
The term organic sales as used in this press release is defined as net sales excluding the impact of currency, acquisitions and divestitures.

Guidance

PPG Anticipates Adj EPS For FY25 Will Be In The Range Of $7.75-$8.05 Vs $8.68 Est.

PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) reported quarterly earnings of $1.61 per share which missed the analyst consensus estimate of $1.65 by 2.42 percent. This is a 3.21 percent increase over earnings of $1.56 per share from the same period last year.

Earnings

PPG Indus Q4 Adj EPS $1.61 Misses $1.65 Estimate

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.03% on an annualized basis producing an average annual return of 14.45%. Currently, Eli Lilly has a market capitalization of $740.34 billion. 
Buying $100 In LLY: If an investor had bought $100 of LLY stock 20 years ago, it would be worth $1,476.91 today based on a price of $823.23 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738280753_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Wells Fargo analyst Donald Fandetti maintains AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) with a Overweight and lowers the price target from $12 to $11.

Price Target

Analyst Ratings

AGNC

Wells Fargo Maintains Overweight on AGNC Investment, Lowers Price Target to $11

Billionaire Jeff Bezos appears to have a major conflict of interest on his hands with a newspaper he owns trying to get records from another<a href="https://www.benzinga.com/news/21/04/20675447/5-things-you-might-not-know-about-jeff-bezos"> company he founded.</a>
What Happened: While he's <a href="https://www.benzinga.com/news/21/07/21849808/jeff-bezos-is-officially-no-longer-the-amazon-ceo">no longer the CEO</a> of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Bezos remains a shareholder and the executive chairman of the company.
This means that a lawsuit filed by Amazon against the Washington Post, which Bezos owns, now has the billionaire on both sides of the legal fight.
The Washington Post is trying to obtain records related to Amazon's Project Kuiper satellite business, <a href="https://www.hollywoodreporter.com/business/business-news/jeff-bezos-amazon-sues-block-records-requests-washington-post-1236121933/">according </a>to The Hollywood Reporter.
Amazon is fighting back and has sued to block the records request as the e-commerce company states releasing the information could be harmful as it contains trade secrets.
The report says items requested by the news outlet include inspection records, investigation notes and complaints related to visits to the company by the Washington Department of Labor and Industries.
Amazon says the records contain proprietary satellite designs and other information that could give competitors "a competitive edge."
Amazon has not sued the newspaper directly, instead filing a lawsuit against a Washington state agency that agreed to disclose the records. The company is not seeking to block the release of all of the requested records, only a small portion that it believes contains trade secrets.
You may not be a billionaire like Jeff Bezos, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/25/01/43201590/benzinga-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-2">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: The news of the battle by The Washington Post against Amazon comes as the newspaper faces public pushback after <a href="https://www.benzinga.com/general/politics/24/10/41557083/jeff-bezos-ends-washington-posts-36-year-tradition-of-endorsements-leaving-staff-roiled">not endorsing a candidate </a>for president for the first time since 1988.
The decision was said to have been made by Bezos, who bought the newspaper in 2013. The move led to the exit of several newspaper workers and saw around 250,000 subscribers cancel their subscriptions as a result.
The battle between The Washington Post and Amazon and the outcome could become a storyline for Bezos and whether or not billionaires should own news outlets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/09/41107170/jeff-bezos-used-this-method-to-get-true-opinions-from-employees-amazon-founder-says-youre-the-b">Jeff Bezos Used This Method To Get True Opinions From Employees: Amazon Founder Says &#8216;You&#8217;re The Boss&#8217;</a></li>
</ul>
Photos: Shutterstock

SPACE

Media

AMZN

Bezos Vs. Bezos: Amazon Files Lawsuit Related To Washington Post In Major Conflict Of Interest For Billionaire

Wells Fargo analyst Larry Biegelsen maintains NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) with a Overweight and raises the price target from $13 to $17.

NPCE

Wells Fargo Maintains Overweight on NeuroPace, Raises Price Target to $17

Wells Fargo analyst Ike Boruchow maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Equal-Weight and lowers the price target from $45 to $40.

VSCO

Wells Fargo Maintains Equal-Weight on Victoria's Secret, Lowers Price Target to $40

Wells Fargo analyst Matthew Akers maintains RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) with a Overweight and raises the price target from $151 to $156.

Wells Fargo Maintains Overweight on RTX, Raises Price Target to $156

Wells Fargo analyst Matthew Akers maintains Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Equal-Weight and lowers the price target from $500 to $497.

Wells Fargo Maintains Equal-Weight on Lockheed Martin, Lowers Price Target to $497

Wells Fargo analyst Derek Archila maintains Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) with a Equal-Weight and lowers the price target from $8 to $6.

ZNTL

Wells Fargo Maintains Equal-Weight on Zentalis Pharma, Lowers Price Target to $6

Wells Fargo analyst Zachary Fadem maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Equal-Weight and raises the price target from $145 to $175.

Wells Fargo Maintains Equal-Weight on Brinker International, Raises Price Target to $175

Wells Fargo analyst David Lantz maintains Monro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) with a Equal-Weight and lowers the price target from $24 to $20.

MNRO

Wells Fargo Maintains Equal-Weight on Monro, Lowers Price Target to $20

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 15 years by 6.96% on an annualized basis producing an average annual return of 19.23%. Currently, Blackstone has a market capitalization of $135.00 billion. 
Buying $1000 In BX: If an investor had bought $1000 of BX stock 15 years ago, it would be worth $13,976.42 today based on a price of $177.82 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738279807_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Wells Fargo analyst Ike Boruchow maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Underweight and raises the price target from $17 to $21.

Wells Fargo Maintains Underweight on VF, Raises Price Target to $21

UBS analyst Alex Kramm maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Neutral and raises the price target from $79 to $89.

NDAQ

UBS Maintains Neutral on Nasdaq, Raises Price Target to $89

UBS analyst Gregg Orrill maintains PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) with a Buy and lowers the price target from $24 to $22.

UBS Maintains Buy on PG&E, Lowers Price Target to $22

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy and lowers the price target from $30 to $27.

TEVA

UBS Maintains Buy on Teva Pharmaceutical Indus, Lowers Price Target to $27

UBS analyst Timothy Arcuri maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Neutral and lowers the price target from $78 to $70.

UBS Maintains Neutral on Western Digital, Lowers Price Target to $70

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has turned increasingly political in recent years, a move that may have hurt the brand value of the <a href="https://www.benzinga.com/news/global/25/01/43172806/tesla-lost-15-billion-in-brand-value-in-2024-report-says-did-elon-musks-political-push-hurt-ev-giant">electric vehicle company.</a>
While Musk is OK with supporting President Donald Trump and the end of the $7,500 federal tax credit, the billionaire also has his eyes set on a sustainable future.
What Happened: A proposed end to the <a href="https://www.benzinga.com/trading-ideas/25/01/43116755/trumps-plan-to-end-7500-ev-tax-credits-could-be-devastating-for-telsa-rivals-poll-says-could-be-bullish-for-elon-musks-company">$7,500 EV tax credit </a>by Trump is one of the biggest storylines for the electric vehicle sector and Musk is a supporter of making such a change.
Musk and Tesla analysts believe the decision to end the credit would be bad for Tesla in the short term, but ultimately benefit the company in the long term as it would be tougher on competitors.
The Tesla CEO was asked about electric vehicle policies under Trump during the company's<a href="https://www.benzinga.com/news/earnings/25/01/43321103/tesla-q4-earnings-highlights-revenue-miss-eps-miss-ev-updates-automaker-says-2025-will-be-a-seminal-year"> fourth-quarter earnings call.</a>
An analyst asked about plans to reverse the "EV mandate" and potential slowdowns of electric vehicle demand in the U.S. due to regulations.
Musk shied away from the question but did highlight his continued belief on electric vehicles being a big part of the future.
"At this point, I think that sustainable transport is inevitable," Musk said, as shared by <a href="https://insideevs.com/news/749018/musk-q4-call-ev-regulations/">InsideEVs</a>. "I'm highly confident that all transport will be autonomous, electric, including aircraft, and that simply, it can't be stopped."
Musk went on to compare the rise of electric vehicles to the introduction of the internal combustion engine.
"Even if you've been the biggest horse advocate on Earth … like, ‘horses are the way, not these new-fangled automobiles,' you can't stop the advent of the automobile and you can't stop the advent of electric cars. It's going to happen."
The Tesla CEO said the only thing holding back electric vehicles previously was range, which has been solved.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: While investors and analysts wanted to hear about Musk's relationship with Trump, what his role<a href="https://www.benzinga.com/news/global/24/11/41927289/trump-appoints-elon-musk-and-vivek-ramaswamy-to-lead-doge-targeting-bureaucracy-and-65-trillion-federal-spending-we-will-not-go-gently"> at the D.O.G.E. </a>means for his time commitment at Tesla and how Trump's EV policies could shape the industry, the earnings call left many questions unanswered.
Trump has been a vocal critic of electric vehicles and also previously said he would ban autonomous vehicles from U.S. roads, a move that would severely hurt the future growth plan of Tesla and its robotaxis.
New Transportation Secretary Sean Duffy shared in a memo that the previous push by Joe Biden's administration for electric vehicles was "forced" on people.
Musk's comments about the future being all-electric and autonomous go against the commentary of Trump and his administration, which could make the friendship between the billionaire and president an interesting development to watch as Musk will likely have to push for support of autonomous vehicles.
Rivian Automotive CEO RJ Scaringe recently <a href="https://www.benzinga.com/25/01/43279098/rivian-ceo-brushes-off-7500-electric-vehicle-tax-credit-concerns-evs-are-not-a-political-thing">shared a similar commentary</a> of keeping his eyes on the future and ignoring the short-term "speed bumps" created by items like the end of the federal tax credit.
&#8220;I started the company with the view of making highly compelling products, and none of my decision to start Rivian had anything to do with what the policy was going to look like,&#8221; Scaringe said.
Scaringe said that the potential elimination of the $7,500 tax credit would be &#8220;equally applied to all,&#8221; which could mean a level playing field for all companies in the electric vehicle sector.
&#8220;The future of transportation will be electric.&#8221;
Scaringe said policy revisions like this can&#8217;t slow down the long-term trend of electric vehicle growth and the necessity of having more electric vehicles on the road.
&#8220;This is not a political thing. It&#8217;s not like the left wants to move to electrification. It&#8217;s that the future of transportation will be electric.&#8221;
Watch the Tesla fourth-quarter earnings call with Musk below. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43347509/tesla-stock-analysts-highlight-fsd-robotaxis-new-vehicles-for-growth-elon-has-never-sounded-so-bullish">Tesla Analysts Highlight FSD, Robotaxis, New Vehicles For Growth: &#8216;Elon Has Never Sounded So Bullish&#8217;</a></li>
</ul>
Photo: Shutterstock
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; WATCH LIVE: Tesla Q4 2024 Earnings Call &#x7C; $TSLA" width="500" height="281" src="https://www.youtube.com/embed/G2UrBRGrLb0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Politics

TSLA

Elon Musk Brushes Aside Concerns On Trump's EV Policies: 'Sustainable Transport Is Inevitable … It Can't Be Stopped'

Tactile Systems Technology GAAP EPS of $0.21 beats by $0.03, revenue of $73.09M misses by $2.92M

Tactile Systems Technology, Inc. (TCMD) Q3 2024 Earnings Call Transcript

Tactile Systems Technology ( ($TCMD) ) has released its Q3 earnings. Here is a breakdown of the information Tactile Systems Technology presented to...

Tactile Systems Technology Reports Q3 2024 Results, Launches Share Buyback

BTIG downgraded Tactile Systems (TCMD) to Neutral from Buy without a price target following the Q3 report. While the shares are inexpensive and Tac...

Tactile Systems downgraded to Neutral from Buy at BTIG

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Tactile Systems Technology (TCMD – Research Report), with a p...

Piper Sandler Sticks to Their Buy Rating for Tactile Systems Technology (TCMD)

Tactile Systems cut to Neutral at BTIG after Q3 revenue miss

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Boeing's (BA) machinist union ha...

Boeing union to end strike, Palantir reports Q3 beat: Morning Buzz

The healthcare technology market is well-poised for long-term growth, thanks to the growing demand for medical devices, cutting-edge technologies, and changing patient care systems. Thus, it could be wise to buy fundamentally solid healthcare technology stocks Zimmer Biomet Holdings (ZBH), STERIS (STE), and Tactile Systems Technology (TCMD), which are revolutionizing patient care. Keep reading... The integration of AI in healthcare is continuously transforming the operations and processes of the medical field. Companies engaged in the healthcare industry are leveraging artificial intelligence (AI) to advance patients' care and lower costs propelling the medical technology market.
Given the industry's bright prospects, investors could consider investing in sound healthcare technology stocks Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>), STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>), and Tactile Systems Technology, Inc. (<a href="https://stocknews.com/stock/TCMD/">TCMD</a>), which are revolutionizing patient care.
The healthcare industry is undergoing rapid transformation owing to the pandemic, shifting demographics, rapid technological advancements, and rising patient expectations. As a result, healthcare companies are increasingly investing in and <a href="https://mobidev.biz/blog/technology-trends-healthcare-digital-transformation">adapting digital technologies</a> to maintain their competitive edge and offer the best solutions to patients.
Concrete technologies like telemedicine, AI-enabled medical devices, and blockchain electronic health records are <a href="https://www.digitalauthority.me/resources/state-of-digital-transformation-healthcare/">entirely reshaping healthcare processes and operations</a>. These modernized technologies, along with offering operational capabilities, also help companies reduce their costs, enhance operational efficiency, and mitigate other risks.
Blockchain technologies, AI, and the Internet of Things (IoT) have significantly impacted the healthcare sector along with emerging devices and infrastructures that are helping doctors, healthcare organizations, and patients gain immediate access to healthcare information, resulting in better decision-making and treatment options.
Fortune Business Insights projects the global healthcare IT market to grow to $981.23 billion by 2032, <a href="https://www.fortunebusinessinsights.com/healthcare-it-market-109359">exhibiting a CAGR of 15.4%</a>, driven by healthcare information technology opportunities like improving clinical outcomes, reducing human error, improving practice efficiencies, and facilitating care coordination.
Given these favorable market trends, let's look at the fundamentals of the top three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> stocks, starting with the third choice.
Stock #3: Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH operates as a medical technology company globally. It designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products, S.E.T. products, and craniomaxillofacial and thoracic products. It also offers robotic, surgical, and bone cement products.
On November 25, ZBH announced U.S. FDA Premarket Approval Application (PMA) supplement approval for the Oxford&#xAE; Cementless Partial Knee. The partial knee allows surgeons to perform a PKR with improved fixation, better long-term implant survival rate, and improved efficiency in the operating room compared to the Oxford cemented partial knee procedure.
The Oxford cementless partial knee is now the only FDA-approved cementless partial knee implant in the U.S. This marked a revolutionary step offering patients a better range of motion, a more natural feel, and a more stable implant-to-bone fixation.
Also, on November 18, ZBH received the CE Mark certification for its Persona&#xAE; revision knee system. The addition to the Persona segment instills ZBH's commitment to personalized solutions, offering surgeons advanced tools for revision knee arthroplasty.
For the third quarter of 2024, which ended September 30, ZBH's total revenues increased 4% year-over-year to $1.82 billion. The company's adjusted <a href="https://www.investopedia.com/terms/o/operating_profit.asp">operating profit</a> grew 3.5% from the year-ago value to $480.20 million. Adjusted net earnings of ZBH amounted to $353.20 million or $1.74 per common share, up 1.9% and 5.5% year-over-year, respectively.
In addition, the company's free cash flow rose 64.3% from the prior year's quarter to $310 million.
According to the company's updated guidance for fiscal 2024, ZBH projects reported revenue change between 3.5% and 4%. It also expects adjusted EPS in the $7.95 - $8.05 range.
Street expects ZBH's revenue and EPS for the fourth quarter (ending December 2024) to increase 3.9% and 4.3% year-over-year to $2.02 billion and $2.30, respectively. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
ZBH's stock has increased 7.7% over the past month to close the last trading session at $112.02.
ZBH's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Growth, Value, and Quality. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, ZBH is ranked #26 out of 138 stocks.
<a href="https://stocknews.com/stock/ZBH/">Click here</a> to access additional ratings of ZBH for Momentum, Sentiment, and Stability.
Stock #2: STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>)
STE offers infection prevention products and services worldwide. The company operates in three segments: Healthcare; Applied Sterilization Technologies (AST); and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing systems and tracking products, endoscopy accessories, and other equipment.
On October 30, STE declared the distribution of a quarterly interim dividend of $0.57 per share. The dividend is to be paid on December 19, 2024, to shareholders of record at the close of business on November 19, 2024.
With 14 years of consecutive dividend growth, STE pays an annual dividend of $2.28, which translates to a yield of 1.06% at the current share price. Its four-year average dividend yield is 0.86%. And the company's dividend payouts have increased at a 9.5% CAGR over the past three years.
STE's total revenues increased 7.3% year-over-year to $1.33 billion for the third quarter that ended September 30, 2024. The company's gross profit grew 6% from the year-ago value to $578.79 million. Net income attributable to stockholders came in at $150.03 million and $1.51 per share, indicating growth of 30.1% and 30.2% year-over-year, respectively.
Analysts expect STE's revenue for the first quarter (ending June 2025) to grow 6.5% year-over-year to $1.36 billion. For the same quarter, its EPS is expected to increase 12.5% year-over-year to $2.28. Furthermore, the company surpassed the consensus EPS estimates in each of the trailing four quarters.
STE's shares have gained 8% over the past year to close the last trading session at $217.47.
STE's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Stability and Sentiment. Within the Medical – Devices &amp; Equipment industry, STE is ranked #12 out of 138 stocks.
In addition to the POWR Ratings we've stated above, we also have STE ratings for Value, Growth, Quality, and Momentum. Get all STE ratings <a href="https://stocknews.com/stock/STE/">here</a>.
Stock #1: Tactile Systems Technology, Inc. (<a href="https://stocknews.com/stock/TCMD/">TCMD</a>)
TCMD is a medical technology company that develops and provides medical devices to treat underserved chronic diseases. The company offers Flexitouch Plus system and Entre Plus System. It also has a mobile application, Kylee, which helps patients learn about lymphedema.
On October 2, TCMD launched Nimbl&#x2122;, its next-generation pneumatic compression platform for the treatment of upper extremity lymphedema. Nimbl is significantly smaller and lighter than previous device iterations and is indicated for treating patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing.
This important portfolio addition reflects TCMD's commitment to advancing solutions that increase patient access to therapy with a differentiated user experience.
TCMD reported total revenue of $73.09 million, up 5% year-over-year during the third quarter that ended June 30, 2024, and its non-GAAP gross profit grew 10.9% from the year-ago value to $55.10 million. The company's adjusted EBITDA of $10.72 million indicates a growth of 39.3% from the prior year's quarter.
Furthermore, the company's net income came in at $5.16 million and $0.21 per common share for the quarter, respectively.
Street expects TCMD's revenue for the second quarter (ending June 2025) to increase 9.2% year-over-year to $79.95 million, and its EPS for the same period is expected to grow 16.6% year-over-year to $0.23. Also, the company has topped the consensus EPS estimate in three of the trailing four quarters.
Shares of TCMD have surged 49.3% over the past six months and 34.9% over the past year to close the last trading session at $18.93.
TCMD's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
TCMD has an A grade for Value and a B for Quality. The stock is ranked #6 among the 138 stocks in the same industry.
In addition to the POWR Ratings we've stated above, we also have TCMD ratings for Growth, Sentiment, Momentum, and Stability. Get all TCMD ratings <a href="https://stocknews.com/stock/TCMD/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZBH shares were trading at $112.02 per share on Thursday morning, up $1.38 (+1.25%). Year-to-date, ZBH has declined -7.37%, versus a 27.18% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/zbh-ste-tcmd-3-healthcare-technology-companies-revolutionizing-patient-care/>3 Healthcare Technology Companies Revolutionizing Patient Care</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Technology Companies Revolutionizing Patient Care

Virtual Meeting to be held on December 10 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

Comments

Tactile Systems Tech

Tactile Systems Tech (TCMD) Opciones

Tactile Systems Tech (NASDAQ:TCMD) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL